Xtant Medical Q4 Earnings Call Highlights

Operating expenses in the quarter were $18.7 million versus $17.9 million in the comparable 2024 period. General and administrative expense increased to $7.3 million from $5.7 million , driven mainly by $1.4 million of additional expense tied to various compensation plans, Neils said. Sales and marketing expense declined to $10.9 million from $11.7 million , largely due to a $0.9 million reduction in commissions. R&D expense fell to $459,000 from $522,000 .Gross margin in the fourth quarter rose to 54.9% fr ...